Can MDM2 analytical tests performed on core needle biopsy be relied upon to diagnose well-differentiated liposarcoma

Modern Pathology

Volumn 23, Issue 10, 2010, Pages 1301-1306

  Weaver, Joshua ^a   Rao, Priya ^b   Goldblum, John R ^a   Joyce, Michael J ^a   Turner, Sondra L ^a   Lazar, Alexander J F ^b   López Terada, Dolores ^c   Tubbs, Raymond R ^a   Rubin, Brian P ^a,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Core needle biopsy; Fluorescence in situ hybridization; Immunohistochemistry; MDM2 amplification; Molecular diagnostics; Well differentiated liposarcoma

Indexed keywords

PROTEIN MDM2;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LIPOMA; LIPOSARCOMA; NEEDLE BIOPSY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 77957549816     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.106     Document Type: Article

References (13)

1. Dei Tos AP, Pedeutour F. Atypical lipomatous tumour/ well differentiated liposarcoma. In: Fletcher CD, Unni, KK, Mertens, F, (eds). World Health Organization Classification of Tumours Pathology & Genetics of Tumours of Soft Tissue and Bone. IARC Press: Lyon, 2002, pp 35-37.
2. Weiss SW, Goldblum JR. Liposarcoma. Enzinger and Weisss Soft Tissue Tumors. St Louis: Mosby, 2008, pp 477-516.
3. Macarenco RS, Erickson-Johnson M, Wang X, et al. Retroperitoneal lipomatous tumors without cytologic atypia: are they lipomas?: a clinicopathologic and molecular study of 19 cases. Am J Surg Pathol 2009; 33:1470-1476.
4. Weaver J, Goldblum JR, Turner S, et al. Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma. Mod Pathol 2009;22:66-70.
5. Dal Cin P, Kools P, Sciot R, et al. Cytogenetic and fluorescence in situ hybridization investigation of ring chromosomes characterizing a specific pathologic subgroup of adipose tissue tumors. Cancer Genet Cytogenet 1993;68:85-90.
6. Karakousis CP, Dal Cin P, Turc-Carel C, et al. Chromosomal changes in soft-tissue sarcomas. A new diagnostic parameter. Arch Surg 1987;122:1257-1260.
7. Pedeutour F, Suijkerbuijk RF, Forus A, et al. Complex composition and co-amplification of SAS and MDM2 in ring and giant rod marker chromosomes in welldifferentiated liposarcoma. Genes Chromosomes Cancer 1994;10:85-94.
8. Vargas DA, Takahashi S, Ronai Z. Mdm2: A regulator of cell growth and death. Adv Cancer Res 2003;89: 1-34.
9. Binh MB, Garau XS, Guillou L, et al. Reproducibility of MDM2 and CDK4 staining in soft tissue tumors. Am J Clin Pathol 2006;125:693-697.
10. Binh MB, Sastre-Garau X, Guillou L, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 2005;29:1340-1347.
11. Sirvent N, Coindre JM, Maire G, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol 2007;31:1476-1489.
12. Weaver J, Downs-Kelly E, Goldblum JR, et al. Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Mod Pathol 2008;21:943-949.
13. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18.